drugset
drugset / Trial / NCT03224221

Apatinib Combined With Chemotherapy for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment

NCT03224221 ↗

Phase 2 Unknown 189 enrolled The First Affiliated Hospital of Anhui Medical University
RandomizedParallel-groupSingle-blindTreatment

Summary

We conduct the clinical trial to further explore the efficacy and safety of Apatinib combined with chemotherapy in treating recurrent or metastatic esophageal squamous cell carcinoma after the failure of conventional treatments.

Timeline

Start
2017-03-23
Primary completion
2019-01-23
Completion
2019-06-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Rivoceranib Small molecule 500 mg Oral
Background fluorouracil Small molecule — —

Indications

esophageal squamous cell carcinoma